(Total Views: 412)
Posted On: 06/15/2020 1:13:08 PM
Post# of 36541
New BARDA Award: Regeneron Pharmaceuticals, Inc USA
Product Name: REGN-COV2
View Announcement
Description:
Two neutralizing monoclonal antibodies (mAbs) directed to non-overlapping epitopes of SARS-CoV-2 Spike.
Unique Impact:
Using their ‘rapid response’ technologies, Regeneron scientists selected 2 potent, virus-neutralizing human antibodies and scaled up manufacturing with in-house capabilities. The 2 antibodies bind non-competitively to the critical receptor binding domain of the SARS-CoV-2 spike protein, which diminishes the ability of mutant viruses to develop resistance and escape treatment.
Award Amount: $85,094,597
Product Name: REGN-COV2
View Announcement
Description:
Two neutralizing monoclonal antibodies (mAbs) directed to non-overlapping epitopes of SARS-CoV-2 Spike.
Unique Impact:
Using their ‘rapid response’ technologies, Regeneron scientists selected 2 potent, virus-neutralizing human antibodies and scaled up manufacturing with in-house capabilities. The 2 antibodies bind non-competitively to the critical receptor binding domain of the SARS-CoV-2 spike protein, which diminishes the ability of mutant viruses to develop resistance and escape treatment.
Award Amount: $85,094,597
(0)
(0)Scroll down for more posts ▼
